Shabo Salam K, Gargary Khalaf H, Erdeve Omer
Heevi Paediatrics Teaching Hospital, Duhok 42001, Iraq.
College of Medicine, University of Duhok, Duhok 42001, Iraq.
Children (Basel). 2023 Jul 10;10(7):1192. doi: 10.3390/children10071192.
One of the most prevalent illnesses in neonates that needs care and treatment is neonatal jaundice. Several drugs are used as pharmacological modalities for treating hyperbilirubinemia, like intravenous immunoglobulin, D-penicillamine, metalloporphyrin, phenobarbital, zinc sulfate and clofibrate. Previous studies suggest the usefulness of fenofibrate in the treatment of hyperbilirubinemia.
The study aims at assessing the effectiveness of oral fenofibrate in the treatment of indirect neonatal hyperbilirubinemia in full-term neonates.
This is a quasi-experimental study that was conducted at Heevi Pediatrics Teaching Hospital in Duhok, which is located in the Kurdistan Region of Iraq. It involved term infants who had jaundice. The neonates who were eligible for the study were randomly assigned to one of two groups: the intervention group or the control group. Both groups were treated with conventional phototherapy. Fenofibrate was administered in a single oral dose of 10 mg/kg to the participants in the intervention group. Throughout the entirety of the treatment, levels of total serum bilirubin were compared and contrasted between the two groups.
After 12 h of treatment, a statistically significant difference (-value = 0.001) was seen in the serum bilirubin levels between the two groups. The difference in serum bilirubin levels became significantly progressively pronounced after 24, 48, and 72 h. The average time of discharge was 63.6 h for the intervention group and 90.9 h for the control group, and this difference was statistically significant (-value < 0.001).
The time it takes to lower high bilirubin levels in neonates may be shortened by combining conventional phototherapy with a single oral dosage of 10 mg/kg fenofibrate. Consequently, these neonates will experience a shorter hospitalization and an accelerated discharge from the hospital.
新生儿黄疸是新生儿中最常见的需要护理和治疗的疾病之一。几种药物被用作治疗高胆红素血症的药理学方法，如静脉注射免疫球蛋白、D-青霉胺、金属卟啉、苯巴比妥、硫酸锌和氯贝丁酯。先前的研究表明非诺贝特在治疗高胆红素血症方面有用。
本研究旨在评估口服非诺贝特治疗足月新生儿间接性高胆红素血症的有效性。
这是一项在伊拉克库尔德地区杜胡克的赫维儿科教学医院进行的准实验研究。研究对象为患有黄疸的足月儿。符合研究条件的新生儿被随机分为两组：干预组或对照组。两组均接受传统光疗。干预组的参与者口服单剂量10mg/kg的非诺贝特。在整个治疗过程中，比较两组的总血清胆红素水平。
治疗12小时后，两组血清胆红素水平存在统计学显著差异（P值=0.001）。在24、48和72小时后，血清胆红素水平的差异变得更加显著。干预组的平均出院时间为63.6小时，对照组为90.9小时，这一差异具有统计学意义（P值<0.001）。
将传统光疗与单剂量口服10mg/kg非诺贝特相结合，可能会缩短新生儿降低高胆红素水平所需的时间。因此，这些新生儿的住院时间将缩短，出院速度将加快。
